Vor Biopharma Inc. — Form SCHEDULE 13D/A
Filed July 21, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
RA Capital Management, L.P. filed an amended Schedule 13D/A regarding beneficial ownership in Vor Biopharma Inc. (market cap ~$76.1M) on July 21, 2026. The filing document itself does not contain the specific amendment details, ownership percentages, share counts, or dollar amounts—only metadata indicating this is an amendment to a prior disclosure. Without access to the actual amendment content or comparison to the original filing, the concrete changes cannot be specified.
Why this rating
Schedule 13D amendments are routine regulatory filings; absent disclosure of a material change in ownership stake or control position, this is standard periodic reporting.
See more from July 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.